Dementia Consortium signs AbbVie
London | 16 February 2016

AbbVie has joined the Dementia Consortium for the development of new drugs.

The pharmaceutical company joins medical research charity MRC Technology, Alzheimer’s Research UK and Eli Lilly.

The consortium is a global £4 million collaboration between academia, charity and the private sector that aims to find new drug treatments for dementia. This combination is being used to drive early stage drug discovery programmes.

AbbVie brings new resources and capital to the consortium.

Dr Simon Ridley, director of research at Alzheimer’s Research UK, said: “It’s a very positive development to have AbbVie join the Dementia Consortium, strengthening our ability to accelerate the search for effective new treatments for dementia.”

The consortium has awarded more than £1.5 million to early stage drug discovery efforts for neurodegenerative diseases, including projects that target the immune system in a bid to halt nerve cell damage in Alzheimer’s.

Author: Tammy Facey



More IPPro Life Sciences | latest news
AstraZeneca enters China with Plendil
Hogan Lovells boosts capabilities in Japan
Morgan Lewis bags four from K&L Gates
Cobra and CPI enter £1.8 million project
Doctors Without Borders urges lower vaccine prices
IPPro Life Sciences
IPPRO ARCHIVES
BACK ISSUES ONLINE
COMPANY INFO
ABOUT US

THE TEAM


Copyright (C) 2013 Black Knight Media Ltd. All rights reserved. No reproduction without prior authorization